Modern Substance Use Disorders - What's Not on the Med List
Use of tobacco products, marijuana, opioids, herbal supplements and illicit substances is quite common and can have significant impact on safety and efficacy of cancer treatments and pain tolerance. Better understanding of these interactions and how we can help patients navigate their use or cessation will lead to better outcomes with lung cancer treatment.
Providers need to know about the scope of the issues of illicit substance use, or recreational drug use, and to understand how these substances can impact cancer treatments. Understanding is needed for prescribing tobacco cessation medications, and how to use cannabinoids effectively.
We will have two speakers. The first speaker will talk about various tobacco use patterns – cigarette smoking, vaping; what is the latest for prescribing and or assisting with smoking cessation. The second speaker will discuss “Non prescribed drugs: the good, the bad, and the ugly – impact on cancer treatments.” This talk will review the influence of marijuana, opioids and other substances (such as psilocybans).
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pulmonologists.
Upon completion of this activity, participants should be able to do the following:
- Gain comfort and cultural competency in asking patients about other substance use
- Learn to prescribe tobacco cessation treatments
- Be able to understand and discuss implications of marijuana, opioids and other substances with patients respectfully and constructively.
- Linda Martin, MD, MPH
- Matthew Steliga, MD
- Deepti Behl, MD
A list of all meeting faculty and Individual presenter disclosures are linked to their names in the Schedule of Events.
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee website page.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 0.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.75 Certificate of AttendanceThis activity was designated for 0.75 AMA PRA Category 1 Credit™.